On the Move (Company Changes and Promotions) (6/07)
Who went where? In Vivo notes significant recent job changes at medical product companies and other firms in the life sciences industries.
You may also be interested in...
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
The regulatory tools are for use in medical device development.
The US agency plans to hold a virtual workshop that will use breakout sessions to get stakeholder feedback on specific hurdles preventing more pediatric devices coming to market.